Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @frankvinluan
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @frankvinluan
-
ICYMI,
@aimmune won FDA approval Friday for#Palforzia, a peanut allergy therapy. The FDA decision covers kids 4-17 yrs.old... https://xconomy.com/san-francisco/2020/01/31/aimmune-awarded-first-fda-approval-for-a-peanut-allergy-therapy/ …$AIMTHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Palforzia carries an $890 a month wholesale price before any rebates or discounts. But@aimmune says it will offer payment assistant programs that could reduce the cost to as low as $20 a month. The new drug is expected to launch in coming weeks.Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
@aimmune#immunotherapy is not a cure. It's meant to reduce sensitivity so that a reaction to accidental peanut exposure is less severe. But#Palforzia comes with a warning that it can cause side effects, including anaphylaxis.Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
First FDA approval for a
#peanutallergy therapy goes to@aimmune. The decision for#Palforzia covers kids 4-17 who have a confirmed peanut allergy diagnosis https://xconomy.com/san-francisco/2020/01/31/aimmune-awarded-first-fda-approval-for-a-peanut-allergy-therapy/ …$AIMTPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
When it comes to
#CRISPR, size matters. Here's why@mammothbiosci thinks the smaller size of Cas14 gives it advantages for developing new drugs and diagnosticshttps://xconomy.com/san-francisco/2020/01/30/with-45m-mammoth-bio-expects-big-things-from-tiny-crispr-cas14/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Black Diamond Therapeutics sold more shares than initially planned, and topped its targeted price range, raising $201M from its
#IPO. Proceeds will support a Phase 1-ready#cancer drug, as well as further development of its pipeline https://xconomy.com/boston/2020/01/30/black-diamonds-upsized-ipo-raises-201m-to-advance-its-cancer-drug-rd/ …$BDTXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This
@AcceleronPharma drug didn't pan out treating a rare blood disorder or chronic kidney disease. But with positive topline Phs 2 data in#pulmonaryarterialhypertension, some now see blockbuster potential.$XLRN shares shot up 50% Tues. https://xconomy.com/boston/2020/01/28/third-times-the-charm-as-acceleron-drug-shows-early-promise-in-pah/ …#PAHHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
RA Capital led the $50M Series A round for Quench Bio, a discovery-stage
#biotech#startup researching a new approach to treating inflammatory disordershttps://xconomy.com/boston/2020/01/27/quench-bio-springs-from-atlas-with-50m-for-a-new-take-on-inflammation/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
.
@Allergan is selling an experimental autoimmune drug to AstraZeneca, and a commercialized digestive drug to@Nestle, to address antitrust concerns about its pending $63B merger w/@AbbVie https://xconomy.com/national/2020/01/27/allergan-offloads-two-drugs-to-secure-approval-of-merger-with-abbvie/ …$AGN$ABBV$AZNHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Epizyme’s
#cancer drug wins accelerated FDA approval, the first for the company and the first nod for a drug treating the rare soft-tissue cancer epithelioid sarcoma... https://xconomy.com/boston/2020/01/23/epizymes-soft-tissue-cancer-drug-granted-speedy-fda-approval/ …$EPZMHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
FDA rejection letters typically stay private. Correspondence between the agency and
@Sarepta shed light on the thinking that led to the rejection and subsequent approval of Duchenne muscular dystrophy drug#golodirsen https://xconomy.com/boston/2020/01/22/fda-flags-risk-of-infection-kidney-damage-for-sarepta-duchenne-drugs/ …$SRPTHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This new Eli Lilly facility will be built in a part of
#RTP that had been an R&D campus for GlaxoSmithKline and its predecessors for decades. GSK sold the site in 2017, but still leases a small portion.https://twitter.com/ncbiotech/status/1219697340878999553 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ICYMI, Revolution Medicines filed for a $100M
#IPO late last week. Lead#cancer drug is in Phase 1 testing under partnership with Sanofi... https://xconomy.com/san-francisco/2020/01/17/revolution-medicines-maps-out-an-ipo-to-reach-cancers-frontiers/ …$RVMD$SNYHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Details about that deal and more are in Revolution Medicines' S-1 filing: https://www.sec.gov/Archives/edgar/data/1628171/000119312520010145/d799036ds1.htm#toc799036_17 …
$RVMDPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Revolution is the company that acquired Warp Drive Bio in 2018, biotech that was also developing RAS
#cancer drugs. https://xconomy.com/san-francisco/2018/10/16/warp-drives-odyssey-ends-with-a-buyout-to-revolution-not-sanofi/ …$RVMDPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
It got its start in 2015, spinning out of VC firm
@ThirdRockV.#Cancer was not Revolution's initial target, but that focus developed as the University of Illinois technology that formed the basis of the#startup led it to a way to drug RAS. https://xconomy.com/san-francisco/2015/02/04/third-rocks-new-revolution-looks-to-squeeze-more-drugs-from-nature/ …$RVMDPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Revolution Medicines has a lead drug in the clinic under a partnership with
@sanofi. Now it's aiming for a $100M#IPO to advance its pipeline of RAS#cancer drugs: https://xconomy.com/san-francisco/2020/01/17/revolution-medicines-maps-out-an-ipo-to-reach-cancers-frontiers/ …$RVMDPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Less than 2 months after announcing a corporate restructuring, Neon Therapeutics has agreed to an acquisition by BioNTech for $67M in stock. The deal values
$NTGN at $2.18 per share. The#cancer drug developer priced its 2018 IPO at $16 per share. https://xconomy.com/boston/2020/01/16/cancer-drug-developer-biontech-to-buy-neon-therapeutics-in-67m-deal/ …$BNTXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Nektar won't do those tests and it's not waiting to see what the FDA says. Hours after the panel vote, the company announced it will withdraw its application and stop investment in the
#opioid drug,#oxycodegol.$NKTR announcement here:https://www.prnewswire.com/news-releases/nektar-issues-statement-regarding-fda-advisory-committee-vote-for-oxycodegol-300987219.html …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.